Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

INFINITY PHARMACEUTICALS, INC.

Form 8-K December 22, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 17, 2015

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

Delaware (State or other jurisdiction

000-31141 (Commission **33-0655706** (IRS Employer

of incorporation)

File Number)

Identification No.)

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

784 Memorial Drive, Cambridge, MA 02139
(Address of principal executive offices) (Zip Code)
Registrant s telephone number, including area code: (617) 453-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- " Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- " Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- "Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On December 17, 2015, Vito Palombella, Ph.D., Chief Scientific Officer of Infinity Pharmaceuticals, Inc. (the Company) notified the Company of his decision to resign effective January 22, 2016. Dr. Palombella confirmed that he is not resigning as a result of any dispute or disagreement with the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: December 22, 2015

INFINITY PHARMACEUTICALS, INC.

By: /s/ William Bertrand, Jr. William Bertrand, Jr. EVP, General Counsel